[
  {
    "ts": null,
    "headline": "Viatris Stock Slides After Phase 3 Blepharitis Drug Trial Misses Key Target",
    "summary": "The study did not meet its main endpoint of clearing eyelid debris in blepharitis patients.",
    "url": "https://finnhub.io/api/news?id=3bfbee0d7b13575de6a0239cb2c6e9d0c15e781a60df50c7c7afceaf73652aee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752872482,
      "headline": "Viatris Stock Slides After Phase 3 Blepharitis Drug Trial Misses Key Target",
      "id": 136012269,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "The study did not meet its main endpoint of clearing eyelid debris in blepharitis patients.",
      "url": "https://finnhub.io/api/news?id=3bfbee0d7b13575de6a0239cb2c6e9d0c15e781a60df50c7c7afceaf73652aee"
    }
  },
  {
    "ts": null,
    "headline": "Why Viatris (VTRS) Stock Is Falling Today",
    "summary": "Shares of medication company Viatris (NASDAQ:VTRS) fell 3.8% in the afternoon session after its experimental therapy for blepharitis, an inflammatory condition of the eyelids, failed to meet the main goal in a late-stage study.",
    "url": "https://finnhub.io/api/news?id=fcfe450c4b4502c9aef7a325bb4e0dac348324382f7afacbe11cb45d0a8fec59",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752855942,
      "headline": "Why Viatris (VTRS) Stock Is Falling Today",
      "id": 136008037,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Shares of medication company Viatris (NASDAQ:VTRS) fell 3.8% in the afternoon session after its experimental therapy for blepharitis, an inflammatory condition of the eyelids, failed to meet the main goal in a late-stage study.",
      "url": "https://finnhub.io/api/news?id=fcfe450c4b4502c9aef7a325bb4e0dac348324382f7afacbe11cb45d0a8fec59"
    }
  },
  {
    "ts": null,
    "headline": "Major Market Benchmarks Stabilize After Clinching Record Highs, Driving Muted Premarket Action for US Equity Futures",
    "summary": "US equity futures were flat ahead of Friday's opening bell as markets took a breather after new reco",
    "url": "https://finnhub.io/api/news?id=572592c126428dd3a22279ca1515728fd32ead4e46b0c388a475fbbb3f95cf89",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752844260,
      "headline": "Major Market Benchmarks Stabilize After Clinching Record Highs, Driving Muted Premarket Action for US Equity Futures",
      "id": 136005754,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "US equity futures were flat ahead of Friday's opening bell as markets took a breather after new reco",
      "url": "https://finnhub.io/api/news?id=572592c126428dd3a22279ca1515728fd32ead4e46b0c388a475fbbb3f95cf89"
    }
  },
  {
    "ts": null,
    "headline": "Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target",
    "summary": "Viatris  was falling Friday after the pharmaceutical company announced that its eye inflammation treatment didn’t meet its target in a late-stage trial.  Viatris  ’ ophthalmic ointment for patients with blepharitis, a condition causing irritation and swelling of the eyelids, failed to fully clear debris from the eyes in the six-week study, the company said.  Shares were falling 4.1% in premarket trading Friday following the announcement.",
    "url": "https://finnhub.io/api/news?id=054065f444db7a1271c54ecefa17fcd93671b781eac4ad447821a562050ddf95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752842820,
      "headline": "Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target",
      "id": 136006401,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Viatris  was falling Friday after the pharmaceutical company announced that its eye inflammation treatment didn’t meet its target in a late-stage trial.  Viatris  ’ ophthalmic ointment for patients with blepharitis, a condition causing irritation and swelling of the eyelids, failed to fully clear debris from the eyes in the six-week study, the company said.  Shares were falling 4.1% in premarket trading Friday following the announcement.",
      "url": "https://finnhub.io/api/news?id=054065f444db7a1271c54ecefa17fcd93671b781eac4ad447821a562050ddf95"
    }
  },
  {
    "ts": null,
    "headline": "Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis",
    "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis, did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing.",
    "url": "https://finnhub.io/api/news?id=1c3794a1214af618d01d17230a1589a1d4c2f8c47a735108e604cb993507b0da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752836340,
      "headline": "Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis",
      "id": 136006402,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis, did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing.",
      "url": "https://finnhub.io/api/news?id=1c3794a1214af618d01d17230a1589a1d4c2f8c47a735108e604cb993507b0da"
    }
  }
]